Skip to main content

Advertisement

SpringerLink
Log in

Multiples Myelom

Aktuelle Therapiekonzepte und neue Behandlungsstrategien

  • topic 1
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. International Myeloma Working Group (2003) Criteria for the classifi cation of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–757

  2. Kyle RA, Rajkumar SV (2008) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3–9. doi:10.1038/leu.2008.291

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chiecchio L, Dagrada GP, White HE et al (2009) Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 48:624–636. doi:10.1002/gcc.20670

    Article  PubMed  CAS  Google Scholar 

  4. Walker BA, Wardell CP, Brioli A et al (2014) Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J 4:e191. doi:10.1038/bcj.2014.13

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Neben K, Lokhorst HM, Jauch A et al (2012) Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119:940–948. doi:10.1182/blood-2011-09-379164

    Article  PubMed  CAS  Google Scholar 

  6. Greipp PR, Miguel JS, Durie BGM et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420. doi:10.1200/JCO.2005.04.242

    Article  PubMed  Google Scholar 

  7. Neben K, Jauch A, Bertsch U et al (2010) Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95:1150–1157. doi:10.3324/haematol.2009.016436

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Moreau P, Cavo M, Sonneveld P et al (2014) Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression — related death. J Clin Oncol 32:2173–2180. doi:10.1200/JCO.2013.53.0329

    Article  PubMed  CAS  Google Scholar 

  9. Engelhardt M, Terpos E, Kleber M et al (2014) European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99:232–242. doi:10.3324/ haematol.2013.099358

    Article  PubMed  PubMed Central  Google Scholar 

  10. Mohty M, Harousseau J-L (2014) Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica 99:408–416. doi:10.3324/haematol.2013.096149

    Article  PubMed  PubMed Central  Google Scholar 

  11. Harousseau J-L, Avet-Loiseau H, Attal M et al (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 27:5720–5726. doi:10.1200/JCO.2008.21.1060

    Article  PubMed  CAS  Google Scholar 

  12. Velde HJK van de, Liu X, Chen G et al (2007) Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92:1399–1406. doi:10.3324/haematol.11534

    Article  PubMed  Google Scholar 

  13. Barlogie B, Anaissie E, Haessler J et al (2008) Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 113:355–359. doi:10.1002/cncr.23546

    Article  PubMed  Google Scholar 

  14. Kapoor P, Kumar SK, Dispenzieri A et al (2013) Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 31:4529–4535. doi:10.1200/JCO.2013.49.0086

    Article  PubMed  Google Scholar 

  15. Paiva B, Gutiérrez NC, Rosiñol L et al (2012) High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119:687–691. doi:10.1182/blood-2011-07-370460

    Article  PubMed  CAS  Google Scholar 

  16. Palumbo A, Bringhen S, Kumar SK et al (2014) Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. doi:10.1016/S1470-2045(13)70609-0

    Google Scholar 

  17. Rajkumar SV, Jacobus S, Callander NS et al (2010) Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29–37. doi:10.1016/S1470-2045(09)70284-0

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Kleber M, Ihorst G, Groß B et al (2013) Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 13:541–551. doi:10.1016/j.clml.2013.03.013

    Article  PubMed  Google Scholar 

  19. Kleber M, Ihorst G, Terhorst M et al (2011) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1:e35. doi:10.1038/bcj.2011.34

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046–1060. doi:10.1056/NEJMra1011442

    CAS  Google Scholar 

  21. Harousseau J-L, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360:2645–2654. doi:10.1056/NEJMct0805626

    Article  PubMed  CAS  Google Scholar 

  22. Koreth J, Cutler CS, Djulbegovic B et al (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 13:183–196. doi:10.1016/j.bbmt.2006.09.010

    Article  PubMed  CAS  Google Scholar 

  23. Martinez-Lopez J, Blade J, Mateos M-V et al (2011) Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118:529–534. doi:10.1182/blood-2011-01-332320

    Article  PubMed  CAS  Google Scholar 

  24. Fermand J-P, Katsahian S, Divine M et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227–9233. doi:10.1200/JCO.2005.03.0551

    Article  PubMed  CAS  Google Scholar 

  25. Mohty M, Hübel K, Kröger N et al (2014) Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. doi:10.1038/bmt.2014.39

    Google Scholar 

  26. Naumann-Winter F, Greb A, Borchmann P et al (1996) First-line tandem highdose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev

  27. Lokhorst H, Einsele H, Vesole D et al (2010) International Myeloma Working Group consensus statement regarding the current status of allogeneic stemcell transplantation for multiple myeloma. J Clin Oncol 28:4521–4530. doi:10.1200/JCO.2010.29.7929

    Article  PubMed  Google Scholar 

  28. San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917. doi:10.1056/NEJMoa0801479

    Article  PubMed  CAS  Google Scholar 

  29. San Miguel JF, Schlag R, Khuageva NK et al (2013) Persistent overall survival benefit and no increased risk of second malignancies with bortezomibmelphalan- prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31:448–455. doi:10.1200/JCO.2012.41.6180

    Article  PubMed  CAS  Google Scholar 

  30. ayers PM, Palumbo A, Hulin C et al (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118:1239–1247. doi:10.1182/blood-2011-03-341669

    Article  Google Scholar 

  31. Facon T et al (2013) Initial phase 3 results of the first (frontline investigation of lenalidomide + dexamethasone versus standard thalidomide) trial (MM- 020/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT)

  32. Ludwig H, Durie BGM, McCarthy P et al (2012) IMWG consensus on maintenance therapy in multiple myeloma. Blood 119:3003–3015. doi:10.1182/blood-2011-11-374249

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  33. Cavo M, Tacchetti P, Patriarca F et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075–2085. doi:10.1016/S0140- 6736(10)61424-9

    Article  PubMed  CAS  Google Scholar 

  34. Morgan GJ, Gregory WM, Davies FE et al (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119:7–15. doi:10.1182/blood-2011-06-357038

    Article  PubMed  CAS  Google Scholar 

  35. Spencer A, Prince HM, Roberts AW et al (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27:1788–1793. doi:10.1200/JCO.2008.18.8573

    Article  PubMed  CAS  Google Scholar 

  36. Attal M, Lauwers-Cances V, Marit G et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782–1791. doi:10.1056/NEJMoa1114138

    Article  PubMed  CAS  Google Scholar 

  37. McCarthy PL, Owzar K, Hofmeister CC et al (2012) Lenalidomide after stemcell transplantation for multiple myeloma. N Engl J Med 366:1770–1781. doi:10.1056/NEJMoa1114083

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  38. Sonneveld P, Schmidt-Wolf IGH, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMGHD4 trial. J Clin Oncol 30:2946–2955. doi:10.1200/JCO.2011.39.6820

    Article  PubMed  CAS  Google Scholar 

  39. Mateos M-V, Oriol A, Martínez-López J et al (2012) Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120:2581–2588. doi:10.1182/blood-2012-05-427815

    Article  PubMed  CAS  Google Scholar 

  40. Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431–440. doi:10.1016/S1470-2045(11)70081-X

    Article  PubMed  Google Scholar 

  41. Weisel K, Kanz L (2014) Lenalidomide. Recent Results Cancer Res 201:347–357. doi:10.1007/978-3-642-54490-3_21

    Article  PubMed  Google Scholar 

  42. Richardson PG, Sonneveld P, Schuster M et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110:3557–3560. doi:10.1182/blood-2006-08-036947

    Article  PubMed  CAS  Google Scholar 

  43. Herndon TM, Deisseroth A, Kaminskas E et al (2013) U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 19:4559–4563. doi:10.1158/1078-0432.CCR-13-0755

    Article  PubMed  CAS  Google Scholar 

  44. Miguel JS, Weisel K, Moreau P et al (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, openlabel, phase 3 trial. Lancet Oncol 14:1055–1066. doi:10.1016/S1470-2045(13)70380-2

    Article  CAS  Google Scholar 

  45. Ocio EM, Richardson PG, Rajkumar SV et al (2014) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28:525–542. doi:10.1038/leu.2013.350

    Article  PubMed  CAS  Google Scholar 

  46. Lonial S, Vij R, Harousseau J-L et al (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30:1953–1959. doi:10.1200/JCO.2011.37.2649

    Article  PubMed  CAS  Google Scholar 

  47. Lonial S, Kaufman J, Laubach J, Richardson P (2013) Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther 13:1731–1740. doi:10.1517/14712598.2013.847919

    Article  PubMed  CAS  Google Scholar 

  48. San-Miguel J, Bladé J, Shpilberg O et al (2014) Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123:4136–4142. doi:10.1182/blood-2013-12-546374

    Article  PubMed  CAS  Google Scholar 

  49. Donato F, Gay F, Bringhen S et al (2014) Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. Expert Opin Biol Ther 14:1127–1144. doi:10.1517/14712598.2014.908848

    Article  PubMed  CAS  Google Scholar 

  50. Andrulis M, Lehners N, Capper D et al (2013) Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 3:862–869. doi:10.1158/2159- 8290.CD-13-0014

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik V, Universitätsklinikum Heidelberg und Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland

    Elias K. Mai & Hartmut Goldschmidt

Authors
  1. Elias K. Mai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hartmut Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elias K. Mai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mai, E.K., Goldschmidt, H. Multiples Myelom. best practice onkologie 9, 6–15 (2014). https://doi.org/10.1007/s11654-014-0512-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-014-0512-3

Search

Navigation